stockrowAtriCure, Inc.
ATRC Healthcare Medical Instruments & Supplies
AtriCure, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $534.5 million, up 14.9% from fiscal 2024.
- Revenue
- +15.0%
- EPS
- +1,583.9%
- Free cash flow
- −0.73%
- Total debt
- −17.3%
Quarter to September 2026, against a year earlier
Follow ATRC
Alert me
AtriCure, Inc. (ATRC) Revenue
AtriCure, Inc.'s revenue for fiscal 2025 was $534.5M, up 14.9% from $465.3M in fiscal 2024. Over the twelve months to 30 September 2026 it was $589.8M. Over the past ten years it has ranged from $129.8M (fiscal 2015) to $534.5M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 5 consecutive fiscal years. AtriCure, Inc. ranks 25th of 47 Medical Instruments & Supplies companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $534.5M | 14.88% |
| FY2024 | $465.3M | 16.55% |
| FY2023 | $399.2M | 20.84% |
| FY2022 | $330.4M | 20.43% |
| FY2021 | $274.3M | 32.83% |
| FY2020 | $206.5M | (10.52%) |
| FY2019 | $230.8M | 14.47% |
| FY2018 | $201.6M | 15.40% |
| FY2017 | $174.7M | 12.64% |
| FY2016 | $155.1M | 19.54% |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $154.5M | 0.55% |
| Jun 2026 | $153.6M | 8.75% |
| Mar 2026 | $141.2M | 0.53% |
| Dec 2025 | $140.5M | 4.64% |
| 43 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| XRAY DENTSPLY SIRONA Inc. compare | $3.6B |
| MMED MiniMed Group, Inc. compare | $3.0B |
| NVST Envista Holdings Corporation compare | $2.9B |
| ICUI ICU Medical, Inc. compare | $2.2B |
| MMSI Merit Medical Systems, Inc. compare | $1.6B |
| STVN Stevanato Group S.p.A. compare | $1.4B |
| WRBY Warby Parker Inc. compare | $934.7M |
| ATRC AtriCure, Inc. | $589.8M |
| PLSE Pulse Biosciences, Inc compare | $1.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ATRC
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement